Fierce Biotech1d
Unity's eye treatment fails to match Eylea, though analysts still see a path forward
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...
Zacks Investment Research on MSN10h
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Fierce Biotech1d
Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...
Cancer Therapy Advisor1d
Linvoseltamab Under Review for Relapsed/Refractory Multiple Myeloma
The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.
Ophthalmology Times6d
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...
American Lung Association4d
COPD for Life is More than a Catchy Slogan
This health education program aims to help patients living with COPD experience better health outcomes and improved quality ...
Seeking Alpha4d
REGN Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals ... for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma ...